FDA Action Alert: MacroGenics and Amgen
The Pharma Data
DECEMBER 13, 2020
Food and Drug Administration (FDA) ’s focus appears to be on Emergency Use Authorizations (EUAs) for the Pfizer-BioNTech and Moderna COVID-19 vaccines, as the year wraps up there are still some PDUFA dates on the agency’s calendar. Amgen’s ABP 798, a Biosimilar to Genentech’s Rituxan. Read on for this week’s.
Let's personalize your content